Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How has the nasal spray influenza vaccine market size changed in recent years, and what is the outlook ahead?
The nasal spray influenza vaccine market size has grown rapidly in recent years. It will grow from $1.31 billion in 2024 to $1.49 billion in 2025 at a compound annual growth rate (CAGR) of 13.2%. The growth in the historic period can be attributed to increasing vaccine accessibility, rising awareness of flu prevention, growing focus on pediatric vaccination, rising vaccination rates, and increasing preferences for needle-free vaccines.
The nasal spray influenza vaccine market size is expected to see rapid growth in the next few years. It will grow to $2.43 billion in 2029 at a compound annual growth rate (CAGR) of 13.1%. The growth in the forecast period can be attributed to rising demand for convenient immunization, growing incidences of seasonal influenza, increasing government initiatives and support, forecasted growth in geriatric and high-risk populations, and increasing adoption in healthcare settings. Major trends in the forecast period include advancements in vaccine delivery systems, integration of mucosal immunity strategies, technology developments in viral vector platforms, advancements in cold-chain technology, and integration of mRNA technology.
Download Your Free Sample PDF:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp
What are the top economic and technological drivers pushing nasal spray influenza vaccine market growth?
The increasing prevalence of influenza is expected to propel the growth of nasal spray influenza vaccine going forward. Influenza refers to a highly contagious viral infection that primarily affects the respiratory system, causing symptoms such as fever, cough, sore throat, body aches, and fatigue. The increasing prevalence of influenza is primarily due to the frequent genetic mutations of the influenza virus, which enable it to evade existing immunity and spread rapidly among populations. Nasal spray influenza vaccine helps protect against influenza by delivering a weakened form of the virus directly into the nasal passages, stimulating an immune response where the virus typically enters the body. For instance, in June 2024, according to the UK Health Security Agency, a UK-based government agency, between week 40 of 2022 and week 15 of 2023, 1,681 confirmed influenza-related critical care admissions were reported by 108 NHS trusts in England. In comparison, the previous season saw only 182 admissions reported by 114 trusts, increasing to 316 admissions by week 39 of 2022. Therefore, the increasing prevalence of influenza is driving the growth of the nasal spray influenza vaccine market.
How is the nasal spray influenza vaccine market segmented by product, application, and end-user?
The nasal spray influenza vaccine market covered in this report is segmented –
1) By Type: Live Attenuated Influenza Vaccine (LAIV), Inactivated Influenza Vaccine
2) By Administration Method: Single-Dose Administration, Multi-Dose Administration
3) By Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospitals, Clinics, Pharmacies, Online Stores, Other Distribution Channels
5) By End User: Healthcare Providers, Individuals, Government Health Departments, Pharmaceutical Companies
Subsegments:
1) By Live Attenuated Influenza Vaccine (LAIV): Trivalent Live Attenuated Influenza Vaccine (Trivalent LAIV), Quadrivalent Live Attenuated Influenza Vaccine (Quadrivalent LAIV)
2) By Inactivated Influenza Vaccine: Whole Virus Inactivated Vaccine, Split Virus Inactivated Vaccine, Subunit Inactivated Vaccine, Adjuvanted Inactivated Vaccine, High-Dose Inactivated Vaccine
View The Full Market Report:
https://www.thebusinessresearchcompany.com/report/nasal-spray-influenza-vaccine-global-market-report
How are emerging trends transforming the nasal spray influenza vaccine market dynamics?
Major companies operating in the nasal spray influenza vaccine market are focusing on developing innovative formulations such as live attenuated influenza vaccine to enhance immune response and improve patient compliance. A live attenuated influenza vaccine (LAIV) is a flu vaccine made from live, weakened influenza viruses that helps prevent influenza by stimulating the immune system to produce antibodies, providing protection without causing the disease, and offering a more comprehensive immune response through both local and systemic immunity, which enhances the body’s ability to defend against future flu infections. For instance, in September 2024, AstraZeneca Plc, a UK-based pharmaceutical industry company, received approval from the U.S. Food and Drug Administration (FDA) for FluMist, a live attenuated influenza vaccine (LAIV), to be self-administered by adults aged up to 49 years or administered by caregivers to children aged 2 to 17 years, making it the first and only influenza vaccine approved for self- or caregiver-administration in the United States. This approval was based on comprehensive usability studies that demonstrated the ability of individuals to correctly self-administer the vaccine, with 100% of participants delivering a full dose as instructed.
Which leading companies are dominating the nasal spray influenza vaccine market landscape?
Major companies operating in the nasal spray influenza vaccine market are Sanofi Pasteur SA, AstraZeneca PLC, GSK plc, Moderna Inc., CSL Limited, Sinovac Biotech Ltd., Emergent BioSolutions Inc., Serum Institute of India Pvt. Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd., NPO Microgen JSC, Changchun BCHT Biotechnology Co. Ltd., Mitsubishi Tanabe Pharma Corporation, FluGen Inc., BioDiem Ltd, Starpharma Holdings Limited, Codagenix Inc., Nobilon International B.V., KM Biologics Co. Ltd., Altimmune Inc., Mylab Discovery Solutions Private Limited
Which geographic areas are expected to offer the highest growth opportunities in thenasal spray influenza vaccine market?
North America was the largest region in the nasal spray influenza vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasal spray influenza vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
How Can Companies Use The Nasal Spray Influenza Vaccine Market Report to Drive Business Results?
This report provides actionable insights tailored for business use—not academic analysis. Companies can leverage the data to:
• Time market entry or expansion using growth forecasts and CAGR trends.
• Develop competitive products by tracking key technology shifts and user preferences.
• Tailor regional strategies with in-depth geographic data and local market dynamics.
• Benchmark and plan partnerships using competitive landscape insights.
Purchase The Report And Get A Swift Delivery:
https://www.thebusinessresearchcompany.com/customise?id=24326&type=smp
Need Customized Data On Nasal Spray Influenza Vaccine Market?
For companies needing more tailored intelligence, The Business Research Company offers customized consulting and data services. Whether you’re entering new regions, launching innovative products, or assessing M&A opportunities, our experts can develop actionable insights specific to your business objectives.
Request Customized Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24326&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
https://thebusinessresearchcompany.com/
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
